Pancreatic Cancer Research

ResearcherChinese Academy of SciencesActive in the last 2 years

Jieer Ying

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9452-1242; OpenAlex author ID A5048541371. Sources: ClinicalTrials.gov.

Their work

Papers
7 (first author 0, last author 2)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
21
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 trial · 2023: 1 paper, 1 trial · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers

Papers 7

  1. A Chemotherapy Progression Decision Score for Treatment Selection After Initial Assessment in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/mco2.70903↗
  2. Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via the macrophage migration inhibitory facto… Co-author DOI 10.1038/s41392-025-02562-8↗
  3. Single-Molecule Liquid Biopsy Detects Low- and High-Abundance Protein Markers Simultaneously for Pancreatic Cancer Diagnosis. Co-author DOI 10.1021/acs.analchem.4c07031↗
  4. Performance evaluation of a CRISPR Cas9-based selective exponential amplification assay for the detection of KRAS mutations in plasma of patients with advanced… Co-author DOI 10.1136/jcp-2023-208974↗
  5. XYA-2: a marine-derived compound targeting apoptosis and multiple signaling pathways in pancreatic cancer. Last author DOI 10.7717/peerj.16805↗
  6. A benzochalcone derivative synchronously induces apoptosis and ferroptosis in pancreatic cancer cells. Last author DOI 10.7717/peerj.16291↗
  7. Developments in metastatic pancreatic cancer: is gemcitabine still the standard? Co-author DOI 10.3748/wjg.v18.i8.736↗

Trials 2

  1. Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer Principal investigator NCT06393166↗
  2. A Study of AK112 in Advanced Malignant Tumors Principal investigator NCT05214482↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaoqing Guan · 2 shared papers, 2023–2024 · strength 0.52
  2. Yixin Zhang · 1 shared paper, 2026 · strength 0.24
  3. Yuan Ding · 1 shared paper, 2026 · strength 0.24
  4. Gaopeng Li · 1 shared paper, 2026 · strength 0.24
  5. Daqian Xu · 1 shared paper, 2026 · strength 0.24
  6. Weilin Wang · 1 shared paper, 2026 · strength 0.24
  7. Xiaohong Fang · 1 shared paper, 2025 · strength 0.21
  8. Yimin Zhang · 1 shared paper, 2025 · strength 0.21
  9. Xinjian Wang · 1 shared paper, 2025 · strength 0.21
  10. Yue Shen · 1 shared paper, 2024 · strength 0.21
  11. Jinzhao Song · 1 shared paper, 2024 · strength 0.21
  12. Yuhua Zhang · 1 shared paper, 2024 · strength 0.21
  13. Huan Zhang · 1 shared paper, 2026 · strength 0.19
  14. Chao Gao · 1 shared paper, 2026 · strength 0.19
  15. Qian Yu · 1 shared paper, 2026 · strength 0.19
  16. Ruining Gong · 1 shared paper, 2026 · strength 0.19
  17. Shanglong Liu · 1 shared paper, 2026 · strength 0.19
  18. Xiaoya Shi · 1 shared paper, 2026 · strength 0.19
  19. Qinghui Niu · 1 shared paper, 2026 · strength 0.19
  20. Ashok Kumar Saluja · 1 shared paper, 2026 · strength 0.19
  21. He Ren · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.